SCHEMBL7489206

SCHEMBL7489206

CCCN(CCC)c1c(C)nc(-c2ccccc2Cl)nc1OC

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 19/20 0.62
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72741 0.86 CRHR1 (0.75) CRHR1
SCHEMBL7590432 0.85 CRHR1 (0.65) CRHR1L3MBTL1
SCHEMBL7486474 0.80 CRHR1 (0.77) CRHR1L3MBTL1
SCHEMBL61586 0.78 CRHR1 (0.79) CRHR1
SCHEMBL62629 0.76 CRHR1 (0.75) CRHR1
SCHEMBL62708 0.76 CRHR1 (0.75) CRHR1
SCHEMBL7488832 0.76 CRHR1 (1.00) CRHR1
SCHEMBL7491990 0.75 CRHR1 (0.60) CRHR1
SCHEMBL27619836 0.74 CRHR1 (0.73) CRHR1
SCHEMBL7492176 0.73 CRHR1 (0.74) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1636000-A 5-substituted arylpyrimidines NEUROGEN CORP (US) 2005-07-06 CN claimed
EP-1233949-A2 5-SUBSTITUTED ARYLPYRIMIDINES NEUROGEN CORPORATION (US) 2002-08-28 EP claimed
US-20020072521-A1 5-substituted arylpyrimidines NEUROGEN CORPORATION 2002-06-13 US claimed
WO-2001068614-A2 5-SUBSTITUTED ARYLPYRIMIDINES NEUROGEN CORPORATION (US) 2001-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072521-A1 5-substituted arylpyrimidines HTR5A, CRHR1, HTR4 CRHR1 2/4885L3MBTL1 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.